Press Releases

Biotage is pleased to announce the launch of the new Biotage® Extrahera™ LV-200 - a compact, automated sample preparation workstation, dedicated to 96 well arrays for microelution technologies and classical Supported Liquid Extraction (SLE), Solid Phase Extraction (SPE), Phospholipid Detection (PLD) and Protein Precipitation (PPT) formats. The new Biotage® Extrahera™ LV-200 workstation is a GLP capable solution dedicated to 96 well arrays for microelution technol

AlixaRx is pleased to announce that the Company, after fully cooperating with the U.S. Department of Justice (“DOJ”), has reached a Settlement Agreement to resolve certain matters related to alleged violations at the Company’s Norcross, GA pharmacy, which was closed for unrelated business reasons in February 2020. The investigation was based on events alleged to have occurred from 2014 through 2017. AlixaRx contests the allegations and has not agreed to liability, but instea

Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in the treatment of gastric (stomach) cancer. BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. Collectively, th

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2.

Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers. The Clevers group dedicates its activity to the study of the molecular mechanisms of tissue development and cancer of various organs using organoids made

Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its Q1 2021 financial results. Summary of results Solid Core Q1 performance boosted by Growth Drivers and included some one-time items with positive impact on Net Sales for €16 MM in Q1 2021. Core Net Sales* reached €215.4 MM, a 5% year-on-year increase with positive contribution by Growth Drivers and one-offs (includes divestment of a s

Lundbeck South Africa, an affiliate of the global biopharmaceutical company committed to researching, developing and delivering transformative therapies for brain diseases, has recently been recognized as one of the best places to work in South Africa for 2021. During the assessment, the company received outstanding scores across several aspects of their workplace, fostering a workplace environment built on employee commitment, teamwork, integrity, corporate citizenship and the pursuit of exc

AbCellera and Angios GmbH announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy. “Through this collaboration, Angios can focus on advancing their unique scientific insig

Richter-Helm BioLogics GmbH & Co. KG, a leading Germany-based, cGMP compliant biopharmaceutical Contract Development and Manufacturing Organization (CDMO) announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023. “The market for pharmaceutical biotechnology has been continuo

Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA. For more than 40 years, Calvert Laboratories has been workin